Skip to main content

Table 2 Downstream targets of the microRNAs analyzed in tumor and non-tumor lungs of the study patients

From: Profile of epigenetic mechanisms in lung tumors of patients with underlying chronic respiratory conditions

MicroRNAs Downstream targets LC patients LC-COPD patients
Non-tumor Tumor Non-tumor Tumor
miR-21
  PTEN, gene expression 78.5 (59.3) 115.6 (89.7) 82.4 (70.2) 0.26 (0.60)*, §§§
MARCKs, gene expression 0.4 (0.2) 0.5 (0.2) 0.5 (0.5) 0.2 (0.1)*, §
TPM-1, gene expression 2.8 (2.1) 11.0 (10.4)** 5.8 (4.9) 1.8 (1.5)§§
PDCD4, gene expression 5.4 (3.4) 5.2 (4.4) 4.0 (2.5) 1.4 (1.0)§
SPRY-2, gene expression 6.0 (3.3) 8.4 (7.1) 3.4 (1.9) 1.2 (1.0)§§§
miR-200b
  ETS-1, gene expression 4.6 (3.7) 3.3 (2.5) 2.8 (2.5) 0.6 (0.3)§
ZEB-2, gene expression 2.3 (1.3) 3.5 (2.7) 0.7 (0.2)# 0.4 (0.3)§§§
miR-126
  EGFL-7, gene expression 4.0 (2.0) 5.0 (3.0) 5.0 (5.0) 1 (0.7)
TOM-1, gene expression 0.6 (0.3) 2.2 (1.1)*** 1.3 (1.0) 0.8 (0.6)§§§
CRK, gene expression 8.6 (7.1) 21.3 (19.7)* 6.6 (5.8) 3.7 (3.5)§§§
Ang-2, protein content 0.3 (0.1) 0.3 (0.2) 0.3 (0.07) 0.5 (0.2)*, §
Fibulin-3, protein content 0.6 (0.2) 0.6 (0.3) 0.5 (0.2) 0.4 (0.2)
Fibulin-2, protein content 0.04 (0.03) 0.1 (0.04)* 0.04 (0.02) 0.04 (0.03)
Fibulin-5, protein content 0.3 (0.1) 0.4 (0.1) 0.5 (0.1)# 0.5 (0.1)
miR-451
  MIF, gene expression 0.6 (0.8) 2.5 (2.1) ** 1.3 (1.1) 0.3 (0.2) §§§
RAB-14, gene expression 6.3 (5.1) 4.1 (1.9) 1.5 (1.3) ## 2.4 (2.1)
miR-210
  FGFRL-1, gene expression 2.5 (1.8) 3.2 (2.0) 4.1 (2.3) 1.3 (1.0)***, §
EFNA-3, gene expression 0.3 (0.2) 1.0 (0.9)* 0.2 (0.1) 0.1 (0.08)§§
P-62, protein content 0.1 (0.04) 0.3 (0.1)* 0.1 (0.02) 0.3 (0.1)*
LC3II/LC3II, protein content 0.1 (0.05) 0.4 (0.1)*** 0.2 (0.1) 0.4 (0.1)*
Beclin-1, protein content 0.3 (0.09) 0.3 (0.05) 0.2 (0.1) 0.3 (0.1)
BAX, protein content 0.2 (0.06) 0.3 (0.2) 0.2 (0.1) 0.3 (0.2)
BCL-2, protein content 0.04 (0.02) 0.2 (0.1)*** 0.1 (0.04) 0.2 (0.05)**
miR-30a-30p      
  SNAIL-1, gene expression 2.3 (1.4) 3.4 (2.8) 2.8 (1.7) 0.6 (0.4)*, §§§
P53, gene expression 0.4 (0.3) 0.7 (0.5) 0.5 (0.3) 0.3 (0.2)§
CDKN2A, gene expression 4.7 (3.9) 1.9 (1.8)* 9.8 (7.8)# 19.4 (16.5)§§§
P63, gene expression 0.1 (0.08) 0.1 (0.05) 0.8 (0.5)### 0.4 (0.3)*
CDKN1A, gene expression 11.8 (10.4) 5.7 (3.5)* 13.5 (7.7) 6.4 (4.8)**
Ki-67 positive cells, % 42.6 (19.0) 96.5 (3.0)*** 42.6 (19.0) 96.2 (4.7)***
miR-let7c
  k-RAS, gene expression 3.0 (2.0) 2.2 (1.0) 2.7 (2.1) 1.1 (0.5)*, §
  1. Variables are represented as mean (standard deviation)
  2. Abbreviations: miR microRNA, rel.expresion relative expression, prot.content protein content, PTEN phosphatase and tensin homolog 10, MARCKS myristoylated alanine-rich protein kinase C substrate, TPM1 tropomyosin 1 (alpha), PDCD4 programmed cell death 4, SPRY2 sprouty homolog 2, ETS1 v-ets avian erythroblastosis virus E26 oncogene homolog 1, ZEB2 zinc finger E-box binding homeobox 2, EGFL7 EGF-like-domain, multiple 7, TOM1 target of myb1, CRK v-crk avian sarcoma virus CT10 oncogene homolog 17, Ang-2 angiopoietin-2, MIF macrophage migration inhibitory factor, RAB14 member RAS oncogene family 14, FGFRL-1 fibroblast growth factor receptor-like 1, EFNA3 ephrin-A3, LC3 light chain 3, BAX bcl-2 associated X protein, BCL-2 B cell lymphoma-2, SNAIL-1 snail family zinc finger 1, P53 tumor protein p53, CDKN2A cyclin-dependent kinase inhibitor 2A, P63 protein p63, CDKN1A cyclin-dependent kinase inhibitor 1A, and k-RAS Kirsten rat sarcoma viral oncogene homolog 11
  3. §p < 0.05, §§p < 0.01, §§§p < 0.001 between tumor lungs of LC-COPD and tumor specimens of LC patients; *p < 0.05, **p < 0.01, ***p < 0.001 between tumor and non-tumor lungs in either LC or LC-COPD patients; #p < 0.05, ##p < 0.01, ###p < 0.001 between non-tumor specimens of LC-COPD and non-tumor lungs of LC patients. Absence of any statistical symbol means no differences between the study groups